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Abstract
Background: The aim of this study was to examine individual differences in a large sample of complete melatonin profiles
not suppressed by light and search for possible associations between the amount and timing of melatonin secretion and a
multitude of lifestyle variables. The melatonin profiles were derived from saliva samples collected every 30 minutes in dim
light from 85 healthy women and 85 healthy men aged 18–45 years. There was a large individual variability in the amount of
melatonin secreted with peak values ranging from 2 to 84 pg/ml. The onset of melatonin secretion ranged from 18:13 to
00:26 hours. The use of hormonal birth control, reduced levels of employment, a smaller number of days on a fixed sleep
schedule, increased day length and lower weight were associated with an increased amplitude of melatonin secretion. The
use of hormonal birth control, contact lenses, a younger age, and lower ratings of mania and paranoia were associated with
a longer duration of melatonin secretion. An earlier occurrence of the onset of melatonin secretion was associated with an
earlier wake time, more morningness and the absence of a bed partner. Lifestyle and behavioral variables were only able to
explain about 15% of the individual variability in the amount of melatonin secretion, which is likely because of a substantial
genetic influence on the levels of melatonin secretion.
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Introduction
Melatonin is a hormone synthesized and released from the
pineal gland [1]. The master circadian clock, located in the
suprachiasmatic nuclei (SCN) in the hypothalamus, controls the
secretion of melatonin from the pineal gland via a multisynaptic
pathway involving the paraventricular nucleus, spinal cord and
superior cervical ganglion. Typically, melatonin levels begin to
increase before sleep, peak in the early hours of the morning and
decrease to daytime levels after waking. Endogenous melatonin
secretion is suppressed by light according to a dose response curve
[2], such that melatonin can even be suppressed by ordinary
indoor light [3]. The extent of melatonin suppression due to light
is also dependent on prior light exposure, with greater previous
light exposure resulting in less melatonin suppression [4].
The duration of melatonin secretion corresponds to the length
of the dark period as a result of the suppressing effects of melatonin
by light. Thus, in many animals, the duration of the melatonin
profile is an important humoral signal that transmits information
about day length (photoperiod) to the neuroendocrine-gonadal
axis, thereby regulating appropriate seasonal physiological and
behavioral changes. However in humans, the use of indoor
lighting at night results in most humans experiencing a summer
photoperiod year round [5]. Indeed, humans living in mid
latitudes do not typically show seasonal changes in their melatonin
duration despite the changing external photoperiod [6,7].
However, when humans were exposed to extremely long (14 hour)
dark periods, melatonin duration increased, indicating that the
melatonin photoperiodic response in humans remains intact.
Furthermore, the increase in melatonin duration was even evident
when melatonin was measured in dim light, indicating that as in
other animals, the human circadian system has a ‘‘memory’’ for its
recent photoperiodic history [8].
The melatonin rhythm in humans is of interest for at least two
other reasons. First, because melatonin secretion is regulated by
the master circadian clock, the dim light melatonin rhythm is
increasingly being used as a reliable marker of the human master
circadian clock [9], which is located in the SCN. Two commonly
derived circadian phase markers include the dim light melatonin
onset (DLMO), the point in time when melatonin levels begin to
rise in the evening and the dim light melatonin offset (DLMOff),
the point in time when melatonin levels diminish in the morning
[10]. The DLMO is the most reliable circadian phase marker,
more reliable than the DLMOff and phase markers derived from
the core body temperature rhythm [9]. Importantly, the timing of
the DLMO is not necessarily dependent on the amplitude of the
melatonin secretion.
There has also been increasing interest in melatonin because of
its possible role in the etiology of breast cancer. Amongst
numerous effects, melatonin is a potent anti-oxidant and an
anti-inflammatory agent. An anti-cancer role for melatonin in
breast cancer is supported by the finding that human blood rich in
melatonin slows the growth of human breast cancer xenografts in
rats [11]. In humans, indirect evidence includes that night
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exposure at night, have an increased risk for breast [12] and
colorectal cancer. However, there have been mixed findings from
prospective studies on whether or not melatonin levels in healthy
women are predictive of their future cancer risk [13,14].
The possible connection between melatonin and cancer have
led to an increasing interest in behavioral and lifestyle factors
beyond light exposure, which may influence melatonin concen-
trations, such as age, alcohol consumption, body mass index (e.g.
[15,16]) and numerous medications (e.g. [15,17,18]). However,
many of these studies have estimated melatonin secretion from the
concentration of the melatonin metabolite 6-sulfatoxymelatonin in
a urine sample collected in ambient light immediately after rising.
As subjects are typically instructed to void at bedtime, the entire
melatonin secretion, which begins 2–3 hours prior to habitual
bedtime, may not be measured. Furthermore, a single urine
sample cannot provide information on the duration of melatonin
secretion (DLMO to DLMOff interval) or on the timing of the
DLMO. In our laboratory we regularly measure complete salivary
melatonin profiles in dim light (,10 lux) to estimate the timing of
the circadian clock. We also collect much behavioral and lifestyle
information from our subjects. Thus the aim of this study was to
examine individual differences in the amount of melatonin
secreted and timing (phase) of the melatonin rhythm in a large
sample of complete salivary melatonin profiles not suppressed by
light, and search for possible associations between these melatonin
parameters and a multitude of lifestyle variables, some not
previously examined in the literature.
Methods
Subjects
As part of numerous studies, we have collected complete
baseline salivary melatonin profiles from 170 individual subjects
([19,20,21,22,23,24] and unpublished data). We included all
available complete melatonin profiles for this analysis. The
demographics of the sample are detailed in Tables 1 and 2. All
subjects were nonsmokers, free of medication throughout the
study, except hormonal birth control, and were in self-reported
good health. None reported taking melatonin supplements. One
hundred and thirty two subjects passed a urine drug screen for
common drugs of abuse (the remaining 38 subjects were not
tested). No subject had worked night shifts or flown across more
than 2 time zones in the previous month. Daily use of sunglasses
was recorded by 107 subjects from enrollment in the study to the
day of the phase assessment. If subjects typically wore contact
lenses they were permitted to do so during the study. The entire
protocols of all of the studies conformed to the standards set by the
Declaration of Helsinki and were approved by the Rush University
Medical Center Institutional Review Board. All procedures were
conducted with the prior adequate understanding and written
consent of the subjects.
Protocol
All subjects slept at home and were assigned a 8–9 hour sleep
schedule for 3, 7, 10 or 15 days prior to the baseline phase
assessment of each study, during which we collected their
melatonin profiles. The sleep schedules were assigned to match
each subject’s sleep reported habitual sleep times. However, 11 of
the 170 subjects (6.5%) were assigned sleep schedules that varied
from their self reported habitual sleep schedule by more than
1 hour but less than 2 hours. During their scheduled sleep times
subjects were instructed to lie in bed and try to sleep. They were
not permitted to read, watch TV, listen to music or talk on the
telephone at this time. To ensure compliance subjects were
required to call the laboratory voice mail (time and date of call was
recorded) before turning out their lights at night and at their wake
time in the morning each day. Subjects also wore a wrist
actigraphy monitor (Ambulatory Monitoring BMA-32, Ardsley
NY or Actiwatch-L, Mini-Mitter, Bend OR) which recorded their
activity every minute and was downloaded and inspected in their
presence every 1–3 days. Subjects also completed daily logs noting
the time and dose of any caffeinated beverages, alcohol, and
medications they consumed that day.
Phase assessment
Each subject experienced a baseline dim light phase assessment
in the laboratory to determine their endogenous melatonin profile.
The light in the phase assessment room was generated from 4
ceiling fixtures, each of which contained 3 fluorescent tubes (GE
32 watt 4100K F32T8-SPX41) which were behind a red filter
(Rosco E-colour RS0248). The light in the adjoining bathroom
was generated by 2 light fixtures, each of which contained 1
incandescent bulb (GE 90 watt Miser). All light fixtures were
controlled by dimmer switches and each switch was locked to a
low setting. During the phase assessment, subjects were seated in
recliners in dim light (always ,10 lux, at the level of the subjects’
eyes, in the direction of gaze, measured at least every 4 hours with
a Minolta TL-1 light meter, Ramsey, NJ) for at least 20 hours.
After no more than 45 minutes in the dim light, subjects began to
give a saliva sample every 30 minutes using Salivettes (Sarstedt,
Newton, NC). During the session subjects were kept awake and
talked amongst each other, watched a dimmed TV (,10 lux) or
listened to music. Non-steriodal anti-inflammatory drugs were not
permitted for at least 72 hours before the first saliva sample as
these drugs have been shown to suppress melatonin [25]. Subjects
did not consume any alcohol in at least the 21.5 hours prior to the
Table 1. Means, standard deviation and range of continuous
demographic variables.
Mean (SD) Range
Age (y) 26.15 (6.00) 18 to 45
Weight (kg) 70.10 (13.87) 44.48 to 105.76
Height (m) 1.71 (0.11) 1.35 to 1.98
BMI (kg/m
2) 23.89 (3.16) 16.85 to 30.31
Morningness-eveningness
a 52.11 (9.10) 34 to 75
Sleepiness
b 5.69 (3.16) 0 to 14
Sleep quality
c 2.76 (1.50) 0 to 7
Baseline days
d 11.16 (4.37) 3 to 15
Day length (h)
e 13.16 (1.54) 9.48 to 15.20
Caffeine (50 mg doses per week)
f 9.19 (11.34) 0 to 70
Alcohol (drinks per week)
f 2.45 (2.96) 0 to 18
aAssessed immediately after study enrolment, from the Horne Ostberg
questionnaire [70] in all 170 subjects.
bAssessed immediately after study enrolment, from the Epworth Sleepiness
Scale [71] in 132 subjects. Scores of greater than 10 are suggestive of high
daytime sleepiness.
cAssessed immediately after study enrolment, from the Pittsburgh Sleep Quality
Index [72] in 132 subjects. A score of greater than 5 is suggestive of a sleep
disorder.
dNumber of days on fixed sleep schedule prior to phase assessment.
eSunrise to sunset times in Chicago (US Naval Observatory).
fSelf-reported habitual use prior to start of study.
doi:10.1371/journal.pone.0003055.t001
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arrival to ensure their blood alcohol concentration was zero.
Subjects did not drink caffeine for at least 6 hours before the first
saliva sample. Toothpaste or mouthwash were not allowed during
the phase assessments. Small caffeine-free snacks and fluids were
permitted, except in the 10 minutes before each sample, and
subjects were required to rinse and brush their teeth with water
while remaining seated 10 minutes before each sample if they had
consumed food or drink. Subjects were occasionally allowed out of
the recliners to use the toilet facilities (also ,10 lux) but had to
remain seated in the 10 minutes before each saliva sample. After
collection, the samples were centrifuged, frozen and later shipped
in dry ice to Pharmasan Laboratories (Osceola, WI) to be
radioimmunoassayed for melatonin. The sensitivity of the assay
was 0.7 pg/ml, and intra- and interassay coefficient of variabilities
were 12.1 and 13.2% respectively.
Data Analysis
The peak value or maximum point of each melatonin profile
was identified. Additionally, area under the curve (AUC) was
calculated for each melatonin profile using the trapezoidal method
[26]. To ensure AUC calculations were not confounded by
differences in the number of saliva samples collected between
studies, longer profiles were truncated to 40 samples by removing
extra low daytime points as needed. Every individual melatonin
profile was visually inspected to ensure the entire profile was
captured by the phase assessment.
The dim light melatonin onset (DLMO) and dim light
melatonin offset (DLMOff) were also calculated. For each
melatonin profile, a threshold was calculated as the mean of 3
low consecutive daytime values plus twice the standard deviation
of these points [27]. Each subject’s DLMO was the point in time
(as determined with linear interpolation) when the melatonin
concentration exceeded and remained above the threshold for at
least 1 hour. The DLMOff was the point in time when melatonin
levels fell and remained below the threshold for at least 1 hour.
The mean (6SD) threshold was 1.860.9 pg/ml. Seven profiles
were of such irregular pattern that these circadian phase markers
could not be reliably determined, and therefore DLMOs and
DLMOffs were only calculated on 163 melatonin profiles.
Statistical Analysis
The statistical analysis included four dependent variables which
were all derived from the melatonin profiles: peak value, AUC,
DLMO, and melatonin duration (DLMO-DLMOff). As the
DLMO can be influenced by environmental light exposure
[28,29], alternative derivations of the DLMO (DLMO to bedtime
interval and sunset to DLMO interval, see Table 3) were also
tested, but as they did not yield unique results only the DLMO was
used in the model reported here. A total of 44 independent
variables were evaluated: the lifestyle and behavioural variables
listed in Tables 1–3, and the 13 subscales of the Minnesota
Multiphasic Personality Inventory-2 (MMPI-2) [30]. Missing
values for the continuous independent variables were replaced
Table 2. Sample size of categorical demographic variables.
Number of subjects
Sex 85 men, 85 women
Hormonal birth control 16 hormonal birth control, 69 no hormonal birth control
Menstrual phase
a 34 follicular, 33 luteal, 2 unknown
Race 104 White, 32 Asian, 23 Black, 11 Other
Ethnicity 14 Hispanic, 156 non Hispanic
Education 3 high school, 68 some college, 44 college graduate, 44 higher degree, 11 unknown
Employment 35 unemployed, 116 student and/or part time work, 19 full time work
Living condition 37 alone, 133 not alone
Bed partner 41 bed partner, 129 no bed partner
Season 40 spring, 88 summer, 20 fall, 22 winter
Eyeglasses 61 wore eyeglasses, 68 no eyeglasses, 41 unknown
Contact lenses 55 wore contacts, 74 no contacts, 41 unknown
Sunglasses 93 yes sunglasses, 14 no sunglasses, 63 unknown
Caffeine in saliva 25 had caffeine in saliva, 145 had no caffeine in saliva
aMenstrual phase is only reported for females not using hormonal birth control.
doi:10.1371/journal.pone.0003055.t002
Table 3. Melatonin profile characteristics and sleep times.
Mean (SD) Range
Peak value (pg/ml) 17.64 (12.48) 2.40 to 83.60
Area under the curve (pg/ml/0.5 h) 235.68 (155.73) 43.95 to 1063.29
DLMO (time) 20:50 (1:12) 18:13 to 00:26
DLMOff (time) 08:21 (1:25) 04:54 to 12:38
DLMO to DLMOff (h) 11.52 (1.25) 7.89 to 14.70
DLMO to bedtime (h) 2.65 (1.04) 20.30 to 5.79
Sunset to DLMO (h) 1.59 (1.68) 21.44 to 6.92
Prestudy bedtime 00:10 (0:55) 22:02 to 03:02
Prestudy wake time 08:11 (1:01) 05:43 to 12:04
Prestudy time in dark (h) 8.01 (0.76) 6.22 to 12.88
Assigned bedtime 23:28 (0:47) 22:00 to 02:00
Assigned wake time 07:31 (0:48) 06:00 to 10:00
Assigned time in dark (h) 8.05 (0.20) 8.00 to 9.00
doi:10.1371/journal.pone.0003055.t003
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independent variables were replaced with the hot-deck method
[31].
A multivariate analysis was planned using structural equation
modeling. The analytic model used to describe these data had a
multivariate melatonin response with the four dependent variables
used as manifest measures of the underlying melatonin response
(n=163). Potential predictors were entered into the model one at a
time, and were discarded if the model failed to fit the data, or the t-
statistic associated with the most recently entered predictor was
below 1.50. Overall model fit was determined when the relative
chi-square (chi-square divided by df) was below 2.00 and the root
mean square error of approximation (RMSEA) was below 0.05.
The final model selected had structural equation coefficients with
one-tailed probabilities less than 0.05. If the model was significant,
univariate stepwise regressions were planned to further explore
each dependent variable. Statistical significance was determined at
p,0.05.
Results
Figure 1 illustrates the variability in the individual melatonin
profiles collected and that some low secretors had a normally
shaped melatonin rhythm while other low secretors did not. Using
our method, we were able to calculate DLMOs and DLMOffs for
the low secretors in B, C and D, but not for the low secretor in A.
Figure 2 illustrates the positively skewed distributions observed in
the peak value and AUC, and the normal distributions observed in
the DLMO and DLMO-DLMOff duration. For statistical
analyses, peak value and AUC were normalized with a natural
log transformation, although the means of peak value and AUC
reported in the text and figures are of the untransformed variables.
The mean, standard deviation and range of the peak value, AUC,
DLMO, DLMOff and DLMO to DLMOff duration are shown in
Table 3. AUC and peak value were significantly and highly
correlated (r=0.96, p,0.001). Peak value and DLMO-DLMOff
duration were significantly correlated (r=0.35, p,0.001) as was
AUC and DLMO-DLMOff duration (r=0.46, p,0.001). There
was no significant correlation between DLMO and peak value or
AUC (both r#0.11, p$0.15).
The final structural equation model fit the data well (chi-
square=25.35, df=26, relative chi-square=0.98, RMSEA=
0.001). There were four significant predictors of melatonin
response in the model: age (r=.18), a dummy-coded measure of
level of employment (r=0.14), a dummy-coded measure of use of
birth control pills (r=2.18) and two scales from the MMPI-2,
paranoia (r=.17) and hypomania (r=.17). The results of the
univariate stepwise regressions (n=170 for peak value and AUC,
n=163 for DLMO and DLMO-DLMOff) are described below.
The regressions were only able to explain 14.8, 13.7, 35.7 and
14.6% of the variance in the peak value, AUC, DLMO and
DLMO-DLMOff duration respectively.
Age, Sex, Hormonal Birth Control, Menstrual Phase
Increasing age was associated with a shorter DLMO-DLMOff
duration (B=20.04, p,0.03), but not with any of the other
Figure 1. Six individual melatonin profiles determined from half hourly saliva samples collected in dim light. Shown are two
melatonin profiles with the lowest AUC (A, B), two melatonin profiles with low AUC but normally shaped melatonin profiles (C, D), and two melatonin
profiles with the highest AUC (E, F). The profiles are plotted with reference to assigned bedtime. The peak value of each profile is shown above the
corresponding point on the profile. The threshold used to determine the DLMO and DLMOff is represented by the horizontal line. The DLMO and
DLMOff are indicated by arrows.
doi:10.1371/journal.pone.0003055.g001
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DLMO-DLMOff duration decreased by 0.36 hours. Sex and
menstrual phase were not significantly associated with any of the
melatonin parameters. Use of hormonal birth control was
associated with a higher peak value (B=0.41, p,0.02), higher
AUC (B=0.37, p,0.02) and a longer DLMO-DLMOff duration
(B=0.64, p,0.05). Figure 3 shows the mean melatonin profiles of
females who used hormonal birth control, females who did not use
hormonal birth control and males.
Weight, Height, Body Mass Index (BMI)
Increased weight was associated with a lower peak value
(B=20.008, p,0.05) and a lower AUC (B=20.006, p,0.05),
such that an additional 10 kgs (about 22 lbs) corresponded to a
reduction in peak value of 9.93 pg/ml and reduction in AUC of
9.94 pg/ml/0.5 h. Height and BMI were not associated with any
of the melatonin parameters.
Race, Ethnicity, Education, Employment, Living
Condition, Bed Partner
Race, ethnicity (NIH classification), education level and living
condition were not associated with any melatonin parameter.
However there were effects of employment status. For this analysis
students and part-time workers were grouped together because
many students also worked part-time. Increased levels of
employment were associated with reduced AUC (B=20.17,
p=0.03). Figure 4 shows the mean melatonin profiles of the
unemployed, student/part-time workers and full-time workers.
Having a bed partner was associated with a later DLMO
(B=20.37, p,0.05), on average a 0.37 hour delay in the DLMO.
Morningness-Eveningness, Sleepiness, Sleep Quality,
Personality
Table 1 shows the mean morningness-eveningness, sleepiness
and sleep quality scores. These were all assessed immediately after
Figure 2. The frequency distributions of peak value, area under the curve, time of the DLMO and melatonin duration (DLMO-
DLMOff). The frequency distributions of peak value and area under the curve were positively skewed, while DLMO and DLMO-DLMOff were
normally distributed.
doi:10.1371/journal.pone.0003055.g002
Figure 3. The mean melatonin profiles of females using (‘‘BC’’,
n=16) or not using hormonal birth control (‘‘no BC’’, n=69)
and males (n=85). The profiles are plotted with reference to assigned
bedtime. Error bars represent SEMs.
doi:10.1371/journal.pone.0003055.g003
Figure 4. The mean melatonin profiles of the unemployed
(n=35), students and/or part-time workers (n=116) and full-
time workers (n=19). The profiles are plotted with reference to
assigned bedtime. Error bars represent SEMs.
doi:10.1371/journal.pone.0003055.g004
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morningness (higher score) was associated with an earlier DLMO
(B=20.03, p,0.01). Sleepiness (from the Epworth Sleepiness
Scale) and sleep quality (from the Pittsburgh Sleep Quality Index)
were not associated with any melatonin parameter. None of the
validity scales (L, F, K) or the clinical scales of Hypochodriasis,
Depression, Hysteria, Psychopathic Deviate, Masculinity-Femi-
ninity, Psychasthenia, Schizophrenia and Social Introversion on
the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) [30]
were associated with any melatonin parameter. However,
increased scores of Hypomania and Paranoia were associated
with a shorter DLMO-DLMOff interval (B=20.02, p,0.05 and
B=20.02, p=0.05 respectively).
Sleep Times, Number of Baseline Days, Day Length,
Season
Mean sleep times are shown in Table 3. Prestudy sleep times
were not associated with any melatonin parameter. An earlier
assigned wake time was associated with an earlier DLMO
(B=0.77, p,0.001), such that for each earlier hour of scheduled
wake time, the DLMO was advanced by 0.77 hours. A greater
number of days on the assigned sleep schedule was associated with
a lower peak value (B=20.04, p,0.001), and a lower AUC
(B=20.03, p,0.01), such that for each additional day of
scheduled sleep, peak value decreased by 0.96 pg/ml and AUC
by 0.97 pg/ml/0.5 h. The summary statistics of day length
(sunrise to sunset) are shown in Table 1. Increased day length
was associated with a higher peak value (B=0.11, p,0.01) and a
higher AUC (B=0.07, p,0.05). For every additional hour of day
length, peak value and AUC increased by 1.12 pg/ml and
1.07 pg/ml/0.5 h respectively. There were no effects of season on
any of the melatonin parameters.
Eyeglasses, Contact Lenses, Sunglasses
There was no effect of eyeglasses or sunglasses use on any
melatonin parameter. However, the use of contact lenses was
associated with a longer DLMO-DLMOff duration (B=20.39,
p,0.05), such that subjects who wore contact lenses had an
average 0.39 hour increase in melatonin duration.
Caffeine, Alcohol
Habitual caffeine and alcohol use was determined from self-
report prior to the start of each study and summary statistics of
these variables are in Table 1. Neither habitual caffeine use or
alcohol use were significantly associated with any melatonin
parameter. Using the daily logs subjects completed during the
studies, we identified 25 subjects who could have had circulating
levels of caffeine during the saliva collection. However there was
no association between circulating levels of caffeine and any of the
melatonin parameters.
Discussion
In this study, 170 salivary melatonin profiles that were sampled
half hourly and not suppressed by light were examined. To our
knowledge this is the largest sample of its kind reported. There was
a large individual variability and a positively skewed distribution in
the amplitude of melatonin secreted (peak value, AUC, Figures 1,
2). Thus it is more unusual to secrete very high amounts of
melatonin than to secrete very low amounts of melatonin
(e.g.[15,32,33]). By contrast, the distributions of the DLMO and
DLMO-DLMOff duration were normally distributed. Previous
research in sheep suggests that the variability in the amount of
melatonin secreted is due to differences in the synthesis, rather
than metabolism, of melatonin [34]. The amount of melatonin
secreted could be due to a multitude of factors, including the
number of functioning (uncalcified) pinealocytes in the pineal
gland [35,36] and the integrity of the retinal-suprachiasmatic
nuclei-pineal pathway [37].
The relationships between melatonin secretion and numerous
behavioral and lifestyle variables were also examined. As detailed
below, several variables had significant associations with the
amount and timing of melatonin secretion; however all of these
variables combined were only able to explain about 15% of the
individual variability in the amount of melatonin (peak value,
AUC, DLMO-DLMOff), but 36% of the individual variability in
the DLMO. Thus all of these significant variables are likely
modifying a strong genetic influence on the amount of melatonin
secretion as indicated by high correlations in the plasma melatonin
levels in monozygotic twins (r=0.94, [38]). Indeed, individual
melatonin profiles often have a characteristic shape that is
reproducible with repeated assessment (e.g. Figure 3 in [20],
Figure 2 in [39]). Below the specific findings and possible
mechanisms are discussed and related to the existing literature.
There was a small effect of age on the duration of melatonin
secretion, but not on the amplitude, which may have been due to
the restricted age range in this study (18–45 years). Many studies
have reported decreasing melatonin levels with increasing age, but
melatonin levels in these studies may have been confounded by
subjects being exposed to ambient light during melatonin
collection, or smoking, drinking alcohol and/or using medication
in close proximity to melatonin collection (e.g.
[15,16,17,32,40,41,42]). The one study that sampled melatonin
frequently in dim light from healthy drug free subjects with ages
ranging from 18 to 81 years, did not find any association between
the AUC of melatonin secreted and age [33].
There was no effect of sex on any of the melatonin parameters.
Furthermore, menstrual phase in women not using hormonal birth
control was not associated with alterations in any of the melatonin
parameters, in agreement with previous studies [39,43,44,45]. Use
of hormonal birth control was significantly associated with
increased melatonin secretion, a result which is at odds with some
epidemiological studies that measured 6-sulfatoxymelatonin
[16,18], but consistent with laboratory studies that measured
melatonin in saliva or plasma [45,46]. While the mechanism is not
clear, this finding is also consistent with estradiol increasing
melatonin synthesis in rat and guinea pig pineal explants [47].
Thus a previous report of an apparent sex difference in melatonin
secretion, with females secreting more melatonin than males [32],
could be because some females in the sample were using hormonal
birth control. Our sample included two female subjects using non-
pill hormonal birth control (implant and vaginal ring), indicating
that only inquiring about oral contraceptive use may overlook
some users of hormonal birth control.
There was an association between weight and melatonin such
that people of heavier weight secreted less melatonin (peak value,
AUC). This finding is consistent with reports of increasing weight
[32] and higher BMI [15,16,17] being associated with lower
amounts of 6-sulfatoxymelatonin in urine. However the mecha-
nism behind this association has not been clearly explained in the
literature [17]. There were no effects of race, ethnicity, education,
or living condition on melatonin. One study has previously
reported increased melatonin secretion in people with higher
education, even after controlling for BMI, alcohol, medication use
and smoking [17]. However while 53% of that sample had
received some college education, over 90% of subjects in our
sample had received some college education. Thus effects of
education on melatonin levels may have been obscured in our
Melatonin Amplitude and Timing
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associated with a later DLMO, although the effect was relatively
small.
To our knowledge, the effect of employment status on
melatonin levels has not been previously examined. As the level
of employment increased, the amount of melatonin secreted, as
indexed by the AUC, decreased (Figure 4). It is not entirely clear
why employment would be associated with AUC but not peak
value. Although the full time workers had earlier prestudy
(habitual) bedtime and wake times than students/part-time
workers and the unemployed (on average at least 0.35 hour
earlier), their prestudy time in dark and scheduled sleep times and
time in dark did not differ. This may explain why there was no
effect of employment on the DLMO-DLMOff duration.
There was no significant association between the amount of
melatonin secreted and morningness-eveningness score, which is
consistent with a previous report [18]. However, as expected,
more morningness was associated with an earlier DLMO. Baseline
sleepiness and sleep quality were not associated with any
melatonin parameter. This is in agreement with previous reports
of no association between sleep architecture and salivary or plasma
melatonin levels in young healthy subjects [48,49] and no
association between the Pittsburgh Sleep Quality Index and
melatonin levels in older healthy subjects [50]. Interestingly,
increased scores of hypomania and paranoia were associated with
a reduced DLMO-DLMOff duration. As individuals with a
hypomania T score .75 (apart from one subject with a T score of
85) and a paranoia T score $75 were excluded from the study,
subjects who scored at higher levels on these subscales likely only
had a tendency towards over activity and a paranoid predispo-
sition [51]. Precisely why these two subscales would relate to
melatonin duration is unclear. To our knowledge the only other
psychological factor associated with melatonin duration is winter
depression. The relationship is in the same direction, but at the
other extreme: winter depression co-occurs with an increased
duration in melatonin [52].
Sleep lengths and season were not significantly associated with
any of the melatonin parameters. An earlier scheduled wake time
was associated with an earlier DLMO, which is consistent with a
previous study which manipulated wake time and found
corresponding shifts in the DLMO [53]. All other sleep times
were not associated with any melatonin parameter. An increasing
number of days on the assigned sleep schedule was associated with
reductions in melatonin amplitude. While the cause of this effect is
unknown, there was a 11.52 pg/ml difference in peak value and
11.64 pg/ml/0.5 h difference in AUC between those subjects on a
fixed sleep schedule for 3 versus 15 days. Consistent with previous
studies of people at mid latitudes, there was no association between
day length and melatonin duration [6,7]. But longer day lengths
were associated with higher peak and AUC levels of melatonin.
Studies conducted at mid latitudes have either not found an effect
of day length on melatonin amplitude [16,17,54], or found that
melatonin amplitude decreases with longer day lengths [15]. One
possible explanation for our results is that longer day lengths in
Chicago likely leads to longer periods of time spent outside and
more exposure to bright outdoor light during the day. Two
research groups have reported that more bright light during the
day can increase melatonin amplitude at night [55,56]. Further
research is needed to fully investigate this possibility.
To our knowledge, this is the first report to explore the
relationship between melatonin levels and use of eyeglasses and
contact lenses. Use of eyeglasses and sunglasses were not associated
with any melatonin parameter. However, use of contact lenses was
associated with an on average 0.39 hour increase in melatonin
duration. In humans, melatonin suppression occurs in response to
short wavelength light as low as 420 nm [57,58], but shorter
wavelengths have not been tested, presumably for safety reasons.
Studies which have used glasses that block light below 530–
540 nm report less melatonin suppression in response to light
[59,60]. As contact lenses typically contain a UV filter, which
blocks wavelengths of less than ,400 nm [61], use of contact lens
may reduce exposure to some short wavelength light. By contrast
the use of eyeglasses still enables at least 7% of light to reach the
eye without passing through the lens [62], presumably from the
periphery. Thus it is possible that our subjects who wore contact
lens received less short wavelength light prior to and during the
saliva collection. A history of less melatonin suppression may have
been reflected in the dim light melatonin profiles collected, or
alternatively less melatonin may have been suppressed during the
saliva collection. Regardless, this finding requires replication and
further investigation.
There was no significant association between self-reported
habitual caffeine use and the timing or amount of melatonin
secreted. This is consistent with a study that reported no difference
in 6-sulfatoxymelatonin levels between subjects who were high and
low caffeine users [17]. Caffeine has a long half-life which ranges
between 2.5 to 10 hours across individuals [63]. On average it
takes 16 hours before a 100 mg dose of caffeine is eliminated and
about 29 hours for a 200 mg dose to be eliminated [63].
Nonetheless, there were no differences in any of the melatonin
parameters between the 25 subjects that likely had circulating
levels of caffeine during the saliva collection and those that did not.
Indeed, there are mixed findings in terms of the effect of caffeine
on melatonin levels [64,65,66,67]. Thus whatever the effects of
caffeine on melatonin, the effect is likely small and the results
suggest that low to moderate caffeine use does not appear to have
any long term effects on melatonin. Alcohol ingestion just prior to
melatonin collection has been shown to decrease melatonin [68].
However, in our study subjects did not drink alcohol for at least
21.5 hours prior to their saliva collection and were breathalyzed
just prior to their first saliva sample to ensure they had zero blood
alcohol concentration. Thus there were no significant associations
between self-reported habitual alcohol use and the timing or
amount of melatonin secretion.
We report these results in the hope that they may aid future
research studies which examine the magnitude and timing of the
melatonin rhythm. There are several factors which may have
increased the variability in the melatonin measurement. It has
recently been reported that the sleep deprivation associated with
overnight phase assessments can reduce melatonin amplitude by
6.7% [69]. This would suggest that the melatonin amplitudes
reported here may be slightly suppressed. Variability in the
melatonin assay would also have contributed to variability in the
melatonin results. However, due to the typically rapid rise in
melatonin levels, assay variability likely had a greater effect on the
estimates of AUC and peak value, than on the DLMO, DLMOff
and melatonin duration. Despite these sources of variability, the
relationships between melatonin and the various lifestyle factors
examined here are not expected to have been systematically
affected.
In summary, the use of hormonal birth control, reduced levels
of employment, a smaller number of days on a fixed sleep
schedule, increased day length and lower weight were associated
with an increased amount of melatonin secretion. The use of
hormonal birth control, contact lenses, a younger age, and lower
ratings of mania and paranoia were associated with a longer
duration of melatonin secretion. An earlier occurrence of the onset
of melatonin secretion was associated with an earlier wake time,
Melatonin Amplitude and Timing
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of the large individual variability in the amount of melatonin
secreted could not be explained, likely because of the large genetic
influence on levels of melatonin secretion. Importantly, high levels
of melatonin do not appear to be necessary to communicate
photoperiodic information to the organism–the duration of
melatonin secretion is likely the critical signal. The melatonin
rhythm as a circadian phase marker is also not affected by the
amplitude of melatonin secretion. Some low secretors failed to
show a readily discernible circadian rhythm in melatonin secretion
(Figure 1 A), but other low secretors exhibited a clear circadian
pattern in their melatonin secretion (Figure 1 C, D). As levels of
melatonin in the blood are approximately three times higher than
in saliva, further detailed examination of low secretors may benefit
by examining plasma melatonin profiles collected in dim light.
Whether low melatonin secretors are at greater risk for breast
cancer is currently unclear [13,14].
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